Rostislav Teodorovich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rostislav Teodorovich has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Evgeniy A. Tkachenko
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Institute of Poliomyelitis, Moscow 108819, Russia
8 shared publications - Aydar A. Ishmukhametov
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis), Moscow 108819, Russia
7 shared publications - Svetlana S. Kurashova
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis)
7 shared publications - Maria S. Egorova
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis)
5 shared publications - Tamara K. Dzagurova
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis)
5 shared publications - Alexandra S. Balkina
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences (Institute of Poliomyelitis)
4 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 26 (3) , 324-335
Vaccines for the prevention of hantavirus fevers: An overview of results and development prospects
INTRODUCTION. Hantavirus fevers, known as hemorrhagic fever with renal syndrome (HFRS) in Eurasia and hantavirus pulmonary syndrome (HPS) in the Americas, are natural focal diseases with a wide range of clinical manifestations. The causative agents are members of the genus Orthohantavirus , whose natural reservoirs are rodents of various species. There is currently no etiotropic therapy for these diseases. Specific prophylaxis through vaccination is available only in the DPRK, the Republic of Korea, and the People's Republic of China. An important objective is to provide the Russian and European markets with a relevant vaccine for HFRS prevention. Such a vaccine should be developed based on both time-proven approaches and the experience of modern developments. AIM. Analysis of the use of existing hantavirus vaccines and the specific features of vaccines under development, as well as assessment of the prospects for creating vaccines for HFRS prevention in the Russian Federation. DISCUSSION. All commercially available vaccine preparations are inactivated whole-virion vaccines based on the Hantaan and Seoul viruses. The effectiveness of these preparations varies, but a significant reduction in the incidence rate in regions with mass vaccination and a low incidence of adverse events have been noted. Several inactivated whole-virion vaccines based on relevant orthohantavirus strains have been developed in Russia. Some of these developments have successfully completed preclinical studies. The spectrum of hantavirus vaccine preparations under development includes subunit vaccines, vaccines based on virus-like particles (VLPs) and viral vectors, DNA vaccines, and mRNA vaccines. The primary immunogens are the surface glycoproteins Gn and Gc of hantaviruses. The closest to implementation into clinical practice are the DNA vaccines based on the Puumala and Hantaan viruses, which have undergone clinical trials (phase I). CONCLUSIONS. No vaccine for the prevention of hantavirus infections developed using virus-like particles (VLPs), viral vectors, or nucleic acids (DNA or mRNA) has undergone a full cycle of clinical trials or been licensed worldwide. On the contrary, well-established traditional technologies for manufacturing inactivated vaccines and their time-proven effectiveness provide a basis for their real prospects of practical application in the Russian Federation and other European countries.
- 5 October 2026
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 26 (3) , 324-335
Open AccessVaccines for the prevention of hantavirus fevers: An overview of results and development prospects
INTRODUCTION. Hantavirus fevers, known as hemorrhagic fever with renal syndrome (HFRS) in Eurasia and hantavirus pulmonary syndrome (HPS) in the Americas, are natural focal diseases with a wide range of clinical manifestations. The causative agents are members of the genus Orthohantavirus , whose natural reservoirs are rodents of various species. There is currently no etiotropic therapy for these diseases. Specific prophylaxis through vaccination is available only in the DPRK, the Republic of Korea, and the People's Republic of China. An important objective is to provide the Russian and European markets with a relevant vaccine for HFRS prevention. Such a vaccine should be developed based on both time-proven approaches and the experience of modern developments. AIM. Analysis of the use of existing hantavirus vaccines and the specific features of vaccines under development, as well as assessment of the prospects for creating vaccines for HFRS prevention in the Russian Federation. DISCUSSION. All commercially available vaccine preparations are inactivated whole-virion vaccines based on the Hantaan and Seoul viruses. The effectiveness of these preparations varies, but a significant reduction in the incidence rate in regions with mass vaccination and a low incidence of adverse events have been noted. Several inactivated whole-virion vaccines based on relevant orthohantavirus strains have been developed in Russia. Some of these developments have successfully completed preclinical studies. The spectrum of hantavirus vaccine preparations under development includes subunit vaccines, vaccines based on virus-like particles (VLPs) and viral vectors, DNA vaccines, and mRNA vaccines. The primary immunogens are the surface glycoproteins Gn and Gc of hantaviruses. The closest to implementation into clinical practice are the DNA vaccines based on the Puumala and Hantaan viruses, which have undergone clinical trials (phase I). CONCLUSIONS. No vaccine for the prevention of hantavirus infections developed using virus-like particles (VLPs), viral vectors, or nucleic acids (DNA or mRNA) has undergone a full cycle of clinical trials or been licensed worldwide. On the contrary, well-established traditional technologies for manufacturing inactivated vaccines and their time-proven effectiveness provide a basis for their real prospects of practical application in the Russian Federation and other European countries.
- Open Access
- 30 April 2026
- Published by Central Research Institute for Epidemiology in Journal of microbiology, epidemiology and immunobiology
- Vol. 103 (2) , 246-257
Immunogenicity of candidate HFRS vaccines based on guinea pig models
Introduction. Cases of hemorrhagic fever with renal syndrome (HFRS) have increased over the past ten years, including in regions previously non-endemic for HFRS. Approximately 98% of all cases in Russia are associated with Puumala hantavirus, while only about 2% of sporadic cases are caused by Hantaan, Amur, Seoul, Kurkino and Sochi hantaviruses. The main HFRS foci are located in the European part of Russia. In endemic areas, the risk of infection exists for all population groups, especially military personnel and workers in the forestry and agricultural sectors. The etiotropic therapy absence can be solved only through vaccination. However, licensed vaccines based on Hantaan or Seoul hantaviruses do not provide protection against Puumala hantavirus, for which no vaccines currently exist worldwide. An experimental vaccine (EV) for the prevention of HFRS, based on Puumala and Hantaan hantaviruses, has been developed at the Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences (Institute of Poliomyelitis). The aim of the study is to determine the EV immunogenicity against HFRS in a guinea pig model using various immunisation schedules. Materials and methods. The induction of neutralising antibodies (NAb) was assessed in the blood serum of guinea pigs following immunisation with mono- and bivalent EV by means of a neutralisation assay based on 50% suppression of focus-forming units in Vero E6 cell culture. The results indicate the formation of a humoral immune response following EV immunisations. Immunogen administration induced the NAb production up to peak values followed by a decrease after certain intervals. Repeated EV administration showed similar NAb dynamics with prolonged circulation. Three variants involving double immunisation and a subsequent booster after one year were prioritised for clinical trials (0, 150, 300; 0, 14, 182, 364; 0, 30, 364). Conclusion. This study indicates the development of a persistent and intense immune response, the strength of which depended on the EV immunisation schedule. The optimal timing for immunogen administration has been determined. The results of this study will be the basis for subsequent clinical trials of hantavirus vaccines.
- 30 April 2026
- Published by Central Research Institute for Epidemiology in Journal of microbiology, epidemiology and immunobiology
- Vol. 103 (2) , 246-257
Open AccessImmunogenicity of candidate HFRS vaccines based on guinea pig models
Introduction. Cases of hemorrhagic fever with renal syndrome (HFRS) have increased over the past ten years, including in regions previously non-endemic for HFRS. Approximately 98% of all cases in Russia are associated with Puumala hantavirus, while only about 2% of sporadic cases are caused by Hantaan, Amur, Seoul, Kurkino and Sochi hantaviruses. The main HFRS foci are located in the European part of Russia. In endemic areas, the risk of infection exists for all population groups, especially military personnel and workers in the forestry and agricultural sectors. The etiotropic therapy absence can be solved only through vaccination. However, licensed vaccines based on Hantaan or Seoul hantaviruses do not provide protection against Puumala hantavirus, for which no vaccines currently exist worldwide. An experimental vaccine (EV) for the prevention of HFRS, based on Puumala and Hantaan hantaviruses, has been developed at the Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of the Russian Academy of Sciences (Institute of Poliomyelitis). The aim of the study is to determine the EV immunogenicity against HFRS in a guinea pig model using various immunisation schedules. Materials and methods. The induction of neutralising antibodies (NAb) was assessed in the blood serum of guinea pigs following immunisation with mono- and bivalent EV by means of a neutralisation assay based on 50% suppression of focus-forming units in Vero E6 cell culture. The results indicate the formation of a humoral immune response following EV immunisations. Immunogen administration induced the NAb production up to peak values followed by a decrease after certain intervals. Repeated EV administration showed similar NAb dynamics with prolonged circulation. Three variants involving double immunisation and a subsequent booster after one year were prioritised for clinical trials (0, 150, 300; 0, 14, 182, 364; 0, 30, 364). Conclusion. This study indicates the development of a persistent and intense immune response, the strength of which depended on the EV immunisation schedule. The optimal timing for immunogen administration has been determined. The results of this study will be the basis for subsequent clinical trials of hantavirus vaccines.
- Open Access
- 7 November 2024
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 23 (5) , 84-91
Epidemiological Analysis of the Incidence of Hemorrhagic Fever with Renal Syndrome and Tick-Borne Encephalitis in the Russian Federation
Relevance. Hemorrhagic fever with renal syndrome (HFRS) and tick-borne encephalitis (TBE) are the most common natural focal diseases of viral etiology in Russia. The medical and social significance of these two infections is determined by the extensive foci of their spread, high annual morbidity rates, and the presence of severe forms of the disease can lead to permanent disability and even death. Aim. To assess the current epidemiological situation of HFRS and TBE in the Russian Federation. Conclusions. Over 23 years (from 2000 to 2022), 164,582 cases of HFRS were identified in Russia with an average annual rate of 4.9 cases per 100 thousand population, as well as 71,579 cases of TBE with an average annual rate of 2.5 cases per 100 thousand population; 668 (0.4%) and 1136 (1.6%) deaths from HFRS and TBE, respectively; 4030 (2.5%) and 9414 (13%) children under the age of 14 years among patients with HFRS and TBE, respectively. The incidence of HFRS and TBE per 100 thousand population of Russia was higher among rural residents than among urban residents. Most cases of HFRS were registered in the autumn-winter period, and TBE – at the end of June – the first half of July. Of the 85 administrative regions of Russia, cases of HFRS and TBE are registered in 42, in 18 – only HFRS, in 13 – only TBE, and in 12 regions no clinically diagnosed cases of HFRS and TBE have been identified.
- 7 November 2024
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 23 (5) , 84-91
Open AccessEpidemiological Analysis of the Incidence of Hemorrhagic Fever with Renal Syndrome and Tick-Borne Encephalitis in the Russian Federation
Relevance. Hemorrhagic fever with renal syndrome (HFRS) and tick-borne encephalitis (TBE) are the most common natural focal diseases of viral etiology in Russia. The medical and social significance of these two infections is determined by the extensive foci of their spread, high annual morbidity rates, and the presence of severe forms of the disease can lead to permanent disability and even death. Aim. To assess the current epidemiological situation of HFRS and TBE in the Russian Federation. Conclusions. Over 23 years (from 2000 to 2022), 164,582 cases of HFRS were identified in Russia with an average annual rate of 4.9 cases per 100 thousand population, as well as 71,579 cases of TBE with an average annual rate of 2.5 cases per 100 thousand population; 668 (0.4%) and 1136 (1.6%) deaths from HFRS and TBE, respectively; 4030 (2.5%) and 9414 (13%) children under the age of 14 years among patients with HFRS and TBE, respectively. The incidence of HFRS and TBE per 100 thousand population of Russia was higher among rural residents than among urban residents. Most cases of HFRS were registered in the autumn-winter period, and TBE – at the end of June – the first half of July. Of the 85 administrative regions of Russia, cases of HFRS and TBE are registered in 42, in 18 – only HFRS, in 13 – only TBE, and in 12 regions no clinically diagnosed cases of HFRS and TBE have been identified.
- Open Access
- 6 September 2024
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 23 (4) , 34-43
Physical and Chemical Inactivators Evaluation for the Puumala Virus Vaccine Technology Development
Relevance. Hemorrhagic fever with renal syndrome (HFRS) is leading among natural focal human diseases in Russia, the causative agents of which - orthohantaviruses - belong to the order Bunyavirales, family Hantaviridae. More than 98% of HFRS cases in Russia are caused by the Puumala virus. It is a serious zoonosis for which there is still no specific treatment. The WHO has not approved a vaccine. The aim of this study was to investigate the effect of formaldehyde, β-propiolactone, hydrogen peroxide, ultraviolet rays, gamma irradiation and thermal inactivation on the immunogenic activity of inactivated vaccine preparations against HFRS Materials and methods. To achieve this aim, experimental vaccine preparations based on the PUU-TKD/VERO strain of Puumala virus were prepared and inactivated using the methods described above. The time intervals required for complete inactivation of the virus were determined, and the effects of the inactivators on viral RNA and immunogenic activity of the vaccine preparations were evaluated in BALB/c mouse and Syrian hamster models. Results. According to our results, vaccine preparations inactivated by different chemical and physical methods, which differ significantly in the mechanism of the mechanism of interaction with the virus, show no significant differences in immunogenic activity, except for thermal inactivation. Conclusion. A certain advantage of β-propiolactone is the short virus inactivation time, its complete degradation into non-toxic compounds within a few hours, and the reduction of total protein content after sterilization filtration, which is probably due to less aggregation of virus particles and cellular proteins
- 6 September 2024
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 23 (4) , 34-43
Open AccessPhysical and Chemical Inactivators Evaluation for the Puumala Virus Vaccine Technology Development
Relevance. Hemorrhagic fever with renal syndrome (HFRS) is leading among natural focal human diseases in Russia, the causative agents of which - orthohantaviruses - belong to the order Bunyavirales, family Hantaviridae. More than 98% of HFRS cases in Russia are caused by the Puumala virus. It is a serious zoonosis for which there is still no specific treatment. The WHO has not approved a vaccine. The aim of this study was to investigate the effect of formaldehyde, β-propiolactone, hydrogen peroxide, ultraviolet rays, gamma irradiation and thermal inactivation on the immunogenic activity of inactivated vaccine preparations against HFRS Materials and methods. To achieve this aim, experimental vaccine preparations based on the PUU-TKD/VERO strain of Puumala virus were prepared and inactivated using the methods described above. The time intervals required for complete inactivation of the virus were determined, and the effects of the inactivators on viral RNA and immunogenic activity of the vaccine preparations were evaluated in BALB/c mouse and Syrian hamster models. Results. According to our results, vaccine preparations inactivated by different chemical and physical methods, which differ significantly in the mechanism of the mechanism of interaction with the virus, show no significant differences in immunogenic activity, except for thermal inactivation. Conclusion. A certain advantage of β-propiolactone is the short virus inactivation time, its complete degradation into non-toxic compounds within a few hours, and the reduction of total protein content after sterilization filtration, which is probably due to less aggregation of virus particles and cellular proteins
- Open Access
- 5 September 2024
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 23 (4) , 4-11
Applied and Theoretical Aspects of the Ecology of Pathogens of Hemorrhagic Fever with Renal Syndrome and Tick-Borne Encephalitis
Relevance. Hemorrhagic fever with renal syndrome (HFRS) and tick-borne encephalitis (TBE) are the most common natural focal diseases of viral etiology In Russia. The medical and social significance of these two infections is determined by the extensive fociof their spread, high annual morbidity rates in the population, and the possibility of developing severe forms of the disease leading to permanent disability and death. The causative agents of HFRS In Russia are 6 types of hantaviruses Hantaan, Amur, Seoul, Puumala, Kurkino and Sochi, which, immunologically and genetically significantly different from each other, support their existence in nature through six different species of small mammals, which are sources of infection in humans. TBE virus strains that cause disease in humans belong to five phylogenetically distinct subtypes, including: Far Eastern, European, Siberian, “178-79” and Baikal. Aim. Analysis of the role of small mammals and ticks in the ecology of HFRS and TBE pathogens. Conclusions. Small mammals retain and transmit hantaviruses to uninfected animals and ticks. At the same time, ticks retain and transmit to ticks and mammals not only the TBE virus, but also hantaviruses. Despite the taxonomic difference between the viruses that cause HFRS and TBE, some of their ecological properties are similar.
- 5 September 2024
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 23 (4) , 4-11
Open AccessApplied and Theoretical Aspects of the Ecology of Pathogens of Hemorrhagic Fever with Renal Syndrome and Tick-Borne Encephalitis
Relevance. Hemorrhagic fever with renal syndrome (HFRS) and tick-borne encephalitis (TBE) are the most common natural focal diseases of viral etiology In Russia. The medical and social significance of these two infections is determined by the extensive fociof their spread, high annual morbidity rates in the population, and the possibility of developing severe forms of the disease leading to permanent disability and death. The causative agents of HFRS In Russia are 6 types of hantaviruses Hantaan, Amur, Seoul, Puumala, Kurkino and Sochi, which, immunologically and genetically significantly different from each other, support their existence in nature through six different species of small mammals, which are sources of infection in humans. TBE virus strains that cause disease in humans belong to five phylogenetically distinct subtypes, including: Far Eastern, European, Siberian, “178-79” and Baikal. Aim. Analysis of the role of small mammals and ticks in the ecology of HFRS and TBE pathogens. Conclusions. Small mammals retain and transmit hantaviruses to uninfected animals and ticks. At the same time, ticks retain and transmit to ticks and mammals not only the TBE virus, but also hantaviruses. Despite the taxonomic difference between the viruses that cause HFRS and TBE, some of their ecological properties are similar.
- Open Access
The Specificity of Epizootic and Epidemiological Processes in Natural Foci of Hemorrhagic Fever with Renal Syndrome and Tick-Borne Encephalitis in Russia, as the Basis for the Prospects of Creating a Combined Vaccine for the Prevention of These Infections
Hemorrhagic fever with renal syndrome (HFRS) and tick-borne encephalitis (TBE) are the most common viral diseases in Russia. HFRS is caused by six different types of hantaviruses: Hantaan, Amur, Seoul, Puumala, Kurkino, and Sochi, which are transmitted to humans through small mammals of the Muridae and Cricetidae families. TBE is caused by viruses belonging to five different phylogenetic subtypes. The similarities in the ecology of HFRS and TBE pathogens is presented here. Hantavirus-infected small mammals can transmit the virus to uninfected animals, and ticks can also transmit hantavirus to other ticks and mammals. Hantavirus transmission from ticks to humans is possible only hypothetically based on indirect data. Over the past 23 years, 164,582 cases of HFRS (4.9 per 105 people) and 71,579 cases of TBE (2.5 per 105 people) were registered in Russia. The mortality rate was 0.4% (668 cases) in HFRS and 1.6% deaths (1136 cases) in TBE. There were 4030 HFRS (2.5%) and 9414 TBE (13%) cases in children under 14 years old. HFRS and TBE cases were registered in 42 out of 85 Russian regions; in 18—only HFRS, in 13—only TBE, and 12 had no reported cases. The prospects of applying a combined vaccine for HFRS and TBE prevention are shown in this paper.
Open AccessThe Specificity of Epizootic and Epidemiological Processes in Natural Foci of Hemorrhagic Fever with Renal Syndrome and Tick-Borne Encephalitis in Russia, as the Basis for the Prospects of Creating a Combined Vaccine for the Prevention of These Infections
Hemorrhagic fever with renal syndrome (HFRS) and tick-borne encephalitis (TBE) are the most common viral diseases in Russia. HFRS is caused by six different types of hantaviruses: Hantaan, Amur, Seoul, Puumala, Kurkino, and Sochi, which are transmitted to humans through small mammals of the Muridae and Cricetidae families. TBE is caused by viruses belonging to five different phylogenetic subtypes. The similarities in the ecology of HFRS and TBE pathogens is presented here. Hantavirus-infected small mammals can transmit the virus to uninfected animals, and ticks can also transmit hantavirus to other ticks and mammals. Hantavirus transmission from ticks to humans is possible only hypothetically based on indirect data. Over the past 23 years, 164,582 cases of HFRS (4.9 per 105 people) and 71,579 cases of TBE (2.5 per 105 people) were registered in Russia. The mortality rate was 0.4% (668 cases) in HFRS and 1.6% deaths (1136 cases) in TBE. There were 4030 HFRS (2.5%) and 9414 TBE (13%) cases in children under 14 years old. HFRS and TBE cases were registered in 42 out of 85 Russian regions; in 18—only HFRS, in 13—only TBE, and 12 had no reported cases. The prospects of applying a combined vaccine for HFRS and TBE prevention are shown in this paper.
- Open Access
- 16 July 2024
- Published by Central Research Institute for Epidemiology in Journal of microbiology, epidemiology and immunobiology
- Vol. 101 (3) , 383-392
The effect of carbohydrate adjuvants in the composition of the experimental hantavirus vaccine on the dynamics of neutralizing antibodies in the blood sera of guinea pigs
Introduction. Vaccination could be the most effective means of preventing hemorrhagic fever with renal syndrome (HFRS), which is one of the leading zoonoses and a major cause of natural disease in humans. Therefore, research to develop an effective vaccine and the search for new non-toxic and effective adjuvants that can enhance and prolong the immune response, reduce the antigen concentration and reduce the frequency of dose administration is an urgent task. The aim of the study was to determine the dependence of the immunogenic activity of an experimental hantavirus vaccine based on Puumala virus (HV) on the antigen dose both in native form and in combination with carbohydrate adjuvants. Materials and methods. The immunoadjuvant effect of Ac3-LPS S. sonnei and S. flexneri 1B and emulsions of nanoemulsified squalene Sepivac SWE (SWE) as part of HV at the optimal and minimal doses was investigated by induction of neutralising antibodies after 3-fold immunisation (day 0, 14, 182) of guinea pigs (Cavia porcellus). Differences in the immunogenic activity of HV were assessed in the neutralisation reaction by 50% suppression of focal units in Vero E6 cell cultures. Results. A statistically significant increase in neutralising antibodies levels was observed after immunization both with HV at the optimal dose and for its combination with adjuvants. Ac3-LPS S. sonnei and SWE showed the most pronounced immunoadjuvant effect at concentrations of 50 and 100 μg/dose, respectively. The immunoadjuvant effect of the combination of the hantavirus vaccine with Ac3-LPS S. sonnei and SWE contributed to both an enhanced immune response and its duration. The tenfold reduction of the antigen dose in the presence of SWE allows optimization of the immune response to the vaccine. Conclusion. The results of this study show the prospects of using Ac3-LPS S. sonnei and Sepivac SWE in the vaccine for the prevention of HFRS.
- 16 July 2024
- Published by Central Research Institute for Epidemiology in Journal of microbiology, epidemiology and immunobiology
- Vol. 101 (3) , 383-392
Open AccessThe effect of carbohydrate adjuvants in the composition of the experimental hantavirus vaccine on the dynamics of neutralizing antibodies in the blood sera of guinea pigs
Introduction. Vaccination could be the most effective means of preventing hemorrhagic fever with renal syndrome (HFRS), which is one of the leading zoonoses and a major cause of natural disease in humans. Therefore, research to develop an effective vaccine and the search for new non-toxic and effective adjuvants that can enhance and prolong the immune response, reduce the antigen concentration and reduce the frequency of dose administration is an urgent task. The aim of the study was to determine the dependence of the immunogenic activity of an experimental hantavirus vaccine based on Puumala virus (HV) on the antigen dose both in native form and in combination with carbohydrate adjuvants. Materials and methods. The immunoadjuvant effect of Ac3-LPS S. sonnei and S. flexneri 1B and emulsions of nanoemulsified squalene Sepivac SWE (SWE) as part of HV at the optimal and minimal doses was investigated by induction of neutralising antibodies after 3-fold immunisation (day 0, 14, 182) of guinea pigs (Cavia porcellus). Differences in the immunogenic activity of HV were assessed in the neutralisation reaction by 50% suppression of focal units in Vero E6 cell cultures. Results. A statistically significant increase in neutralising antibodies levels was observed after immunization both with HV at the optimal dose and for its combination with adjuvants. Ac3-LPS S. sonnei and SWE showed the most pronounced immunoadjuvant effect at concentrations of 50 and 100 μg/dose, respectively. The immunoadjuvant effect of the combination of the hantavirus vaccine with Ac3-LPS S. sonnei and SWE contributed to both an enhanced immune response and its duration. The tenfold reduction of the antigen dose in the presence of SWE allows optimization of the immune response to the vaccine. Conclusion. The results of this study show the prospects of using Ac3-LPS S. sonnei and Sepivac SWE in the vaccine for the prevention of HFRS.
- Open Access
- 5 July 2024
- Published by Central Research Institute for Epidemiology in Problems of Virology
- Vol. 69 (3) , 285-289
Enzyme immunoassay system for serological diagnosis of hemorrhagic fever with renal syndrome based on inactivated purified Puumala virus (Hantaviridae: Orthohantavirus)
Introduction. Hemorrhagic fever with renal syndrome (HFRS) is the most common zoonotic human viral disease in the Russian Federation. More than 98% of the HFRS cases are caused by Puumala orthohantavirus (PUU). Effective serological tests are required for laboratory diagnosis of HFRS. Objective. Construction of an enzyme immunoassay (ELISA) test system for detection of specific antibodies using standard antigen in the form of highly purified inactivated PUU virus as immunosorbent. Materials and methods. Preparation of PUU virus antigen, designing the ELISA for detection of specific antibodies, developing parameters of the ELISA system, parallel titration of HFRS patients sera by fluorescent antibody technique (FAT) and the new ELISA. Results and discussion. For the first time, ELISA based on purified inactivated PUU virus as standard antigen directly absorbed onto immunoplate was developed. Parallel titration of 50 samples from HFRS patients blood sera using FAT and the developed ELISA showed high sensitivity and specificity of this ELISA, with 100% concordance of testing results and significant level of correlation between the titers of specific antibodies in the two assays. Conclusion. The ELISA based on purified inactivated PUU virus as an immunosorbent can be effectively used for HFRS serological diagnosis and for mass seroepidemiological studies.
- 5 July 2024
- Published by Central Research Institute for Epidemiology in Problems of Virology
- Vol. 69 (3) , 285-289
Open AccessEnzyme immunoassay system for serological diagnosis of hemorrhagic fever with renal syndrome based on inactivated purified Puumala virus (Hantaviridae: Orthohantavirus)
Introduction. Hemorrhagic fever with renal syndrome (HFRS) is the most common zoonotic human viral disease in the Russian Federation. More than 98% of the HFRS cases are caused by Puumala orthohantavirus (PUU). Effective serological tests are required for laboratory diagnosis of HFRS. Objective. Construction of an enzyme immunoassay (ELISA) test system for detection of specific antibodies using standard antigen in the form of highly purified inactivated PUU virus as immunosorbent. Materials and methods. Preparation of PUU virus antigen, designing the ELISA for detection of specific antibodies, developing parameters of the ELISA system, parallel titration of HFRS patients sera by fluorescent antibody technique (FAT) and the new ELISA. Results and discussion. For the first time, ELISA based on purified inactivated PUU virus as standard antigen directly absorbed onto immunoplate was developed. Parallel titration of 50 samples from HFRS patients blood sera using FAT and the developed ELISA showed high sensitivity and specificity of this ELISA, with 100% concordance of testing results and significant level of correlation between the titers of specific antibodies in the two assays. Conclusion. The ELISA based on purified inactivated PUU virus as an immunosorbent can be effectively used for HFRS serological diagnosis and for mass seroepidemiological studies.
- Open Access
Safety and Immunogenicity of Inactivated Whole Virion COVID-19 Vaccine CoviVac in Clinical Trials in 18–60 and 60+ Age Cohorts
We present the results of a randomized, double-blind, placebo-controlled, multi-center clinical trial phase I/II of the tolerability, safety, and immunogenicity of the inactivated whole virion concentrated purified coronavirus vaccine CoviVac in volunteers aged 18–60 and open multi-center comparative phase IIb clinical trial in volunteers aged 60 years and older. The safety of the vaccine was assessed in 400 volunteers in the 18–60 age cohort who received two doses of the vaccine (n = 300) or placebo (n = 100) and in 200 volunteers in 60+ age cohort all of whom received three doses of the vaccine. The studied vaccine has shown good tolerability and safety. No deaths, serious adverse events (AEs), or other significant AEs related to vaccination have been detected. The most common AE in vaccinated participants was pain at the injection site (p < 0.05). Immunogenicity assessment in stage 3 of Phase II was performed on 167 volunteers (122 vaccinated and 45 in Placebo Group) separately for the participants who were anti-SARS-CoV-2 nAB negative (69/122 in Vaccine Group and 28/45 in Placebo Group) or positive (53/122 in Vaccine Group and 17/45 in Placebo Group) at screening. On Day 42 after the 1st vaccination, the seroconversion rate in participants who were seronegative at screening was 86.9%, with the average geometric mean neutralizing antibody (nAB) titer of 1:20. A statistically significant (p < 0.05) increase in IFN-γ production by peptide-stimulated T-cells was observed at Days 14 and 21 after the 1st vaccination. In participants who were seropositive at screening but had nAB titers below 1:256, the rate of fourfold increase in nAB levels was 85.2%, while in the participants with nAB titers > 1:256, the rate of fourfold increase in nAB levels was below 45%; the participants who were seropositive at screening of the 2nd vaccination did not lead to a significant increase in nAB titers. In conclusion, inactivated vaccine CoviVac has shown good tolerability and safety, with over 85% NT seroconversion rates after complete vaccination course in participants who were seronegative at screening in both age groups: 18–60 and 60+. In participants who were seropositive at screening and had nAB titers below 1:256, a single vaccination led to a fourfold increase in nAB levels in 85.2% of cases. These findings indicate that CoviVac can be successfully used both for primary vaccination in a two-dose regimen and for booster vaccination as a single dose in individuals with reduced neutralizing antibody levels.
Open AccessSafety and Immunogenicity of Inactivated Whole Virion COVID-19 Vaccine CoviVac in Clinical Trials in 18–60 and 60+ Age Cohorts
We present the results of a randomized, double-blind, placebo-controlled, multi-center clinical trial phase I/II of the tolerability, safety, and immunogenicity of the inactivated whole virion concentrated purified coronavirus vaccine CoviVac in volunteers aged 18–60 and open multi-center comparative phase IIb clinical trial in volunteers aged 60 years and older. The safety of the vaccine was assessed in 400 volunteers in the 18–60 age cohort who received two doses of the vaccine (n = 300) or placebo (n = 100) and in 200 volunteers in 60+ age cohort all of whom received three doses of the vaccine. The studied vaccine has shown good tolerability and safety. No deaths, serious adverse events (AEs), or other significant AEs related to vaccination have been detected. The most common AE in vaccinated participants was pain at the injection site (p < 0.05). Immunogenicity assessment in stage 3 of Phase II was performed on 167 volunteers (122 vaccinated and 45 in Placebo Group) separately for the participants who were anti-SARS-CoV-2 nAB negative (69/122 in Vaccine Group and 28/45 in Placebo Group) or positive (53/122 in Vaccine Group and 17/45 in Placebo Group) at screening. On Day 42 after the 1st vaccination, the seroconversion rate in participants who were seronegative at screening was 86.9%, with the average geometric mean neutralizing antibody (nAB) titer of 1:20. A statistically significant (p < 0.05) increase in IFN-γ production by peptide-stimulated T-cells was observed at Days 14 and 21 after the 1st vaccination. In participants who were seropositive at screening but had nAB titers below 1:256, the rate of fourfold increase in nAB levels was 85.2%, while in the participants with nAB titers > 1:256, the rate of fourfold increase in nAB levels was below 45%; the participants who were seropositive at screening of the 2nd vaccination did not lead to a significant increase in nAB titers. In conclusion, inactivated vaccine CoviVac has shown good tolerability and safety, with over 85% NT seroconversion rates after complete vaccination course in participants who were seronegative at screening in both age groups: 18–60 and 60+. In participants who were seropositive at screening and had nAB titers below 1:256, a single vaccination led to a fourfold increase in nAB levels in 85.2% of cases. These findings indicate that CoviVac can be successfully used both for primary vaccination in a two-dose regimen and for booster vaccination as a single dose in individuals with reduced neutralizing antibody levels.
- Open Access
Cases of Hemorrhagic Fever with Renal Syndrome in Russia during 2000–2022
During 2000–2022, a total of 69 of Russia’s 85 administrative regions reported 164,580 hemorrhagic fever with renal syndrome (HFRS) cases, with an annual average rate of 4.9 cases/100,000 population (105 popul.). European Russia reported 162,045 (98.5%) cases in 53/60 regions with 9.7 cases/105 popul. Asian Russia reported 2535 (1.5%) cases in 16/25 regions with 0.6 cases/105 popul. In the same period, Russia reported 668 (0.4%) fatal HFRS cases, and 4030 (2.4%) cases among children under the age of 14 years. Most HFRS cases occurred during autumn and winter. The incidence among rural residents was 6.7 per 105 popul., higher than the urban 4.4 per 105 popul.; however, among HFRS patients, rural and urban residents account for 35% and 65%, respectively. Six hantaviruses, causing HFRS of different clinical severity, were recognized as pathogens: Hantaan (HTNV) and Amur (AMUV) of Orthohantavirus hantanense species, Seoul (SEOV) of Orthohantavirus seoulense species, Puumala (PUUV) of Orthohantavirus puumalaense species, and Kurkino (KURV) and Sochi (SOCV) of Orthohantavirus dobravaense species, with the principal hosts Apodemus agrarius coreae, Apodemus peninsulae, Rattus norvegicus, Myodes glareolus, Apodemus agrarius agrarius, and Sylvaemus ponticus, respectively. It was found that 97.7% of HFRS cases are caused by PUUV, therefore, this virus plays the main role in the HFRS morbidity structure in Russia.
Open AccessCases of Hemorrhagic Fever with Renal Syndrome in Russia during 2000–2022
During 2000–2022, a total of 69 of Russia’s 85 administrative regions reported 164,580 hemorrhagic fever with renal syndrome (HFRS) cases, with an annual average rate of 4.9 cases/100,000 population (105 popul.). European Russia reported 162,045 (98.5%) cases in 53/60 regions with 9.7 cases/105 popul. Asian Russia reported 2535 (1.5%) cases in 16/25 regions with 0.6 cases/105 popul. In the same period, Russia reported 668 (0.4%) fatal HFRS cases, and 4030 (2.4%) cases among children under the age of 14 years. Most HFRS cases occurred during autumn and winter. The incidence among rural residents was 6.7 per 105 popul., higher than the urban 4.4 per 105 popul.; however, among HFRS patients, rural and urban residents account for 35% and 65%, respectively. Six hantaviruses, causing HFRS of different clinical severity, were recognized as pathogens: Hantaan (HTNV) and Amur (AMUV) of Orthohantavirus hantanense species, Seoul (SEOV) of Orthohantavirus seoulense species, Puumala (PUUV) of Orthohantavirus puumalaense species, and Kurkino (KURV) and Sochi (SOCV) of Orthohantavirus dobravaense species, with the principal hosts Apodemus agrarius coreae, Apodemus peninsulae, Rattus norvegicus, Myodes glareolus, Apodemus agrarius agrarius, and Sylvaemus ponticus, respectively. It was found that 97.7% of HFRS cases are caused by PUUV, therefore, this virus plays the main role in the HFRS morbidity structure in Russia.